BIZ DESK
Shares of Windlas Biotech witnessed a sharp upward movement, surging over 12% following the release of the company’s standalone financial results for the quarter ended June 2026. The stock had closed at ₹839.65 on August 7, 2026, on the National Stock Exchange (NSE) before seeing a strong buying momentum driven by double-digit revenue expansion.
Key Standalone Financial Highlights (Q1 June 2026)
- Net Sales: Reported at ₹248.10 crore, marking an impressive 18.09% increase compared to ₹210.09 crore in June 2025.
- Net Profit: Stood steady at ₹17.65 crore, reflecting a negligible change from ₹17.67 crore in the corresponding quarter last year.
- EBITDA: Recorded at ₹31.80 crore, remaining stable compared to ₹31.77 crore reported in Q1 FY25.
- Earnings Per Share (EPS): Marginally increased to ₹8.46 for June 2026, up from ₹8.43 in June 2025.
Market Reaction and Outlook
The robust top-line growth of over 18% has significantly boosted investor confidence, triggering aggressive buying in the counter and propelling the stock up by more than 12%. While profitability and core operating earnings remained flat year-on-year, the strong acceleration in net sales highlights healthy operational scale and robust demand for the company’s contract manufacturing and pharmaceutical products.
Disclaimer: This article is strictly for informational purposes and does not constitute financial or investment advice. Investors are advised to consult with a qualified financial advisor before making any investment decisions.